Neoantigens are novel mutated peptides only present within tumour cells. In comparison to conventional immunotherapies, neoantigen-based immunotherapy promotes more potent anti-tumour immune responses with less adversity and off-target consequences. Neoantigen peptides are essential for in vitro functionality screening, pre-clinical trial analysis, and post-clinical efficacy screening when developing personalized cancer vaccines (PCVs) or allogeneic/autologous T-cell treatments (ATCT). However, because of their severe hydrophobicity and other physiochemical characteristics, it is very difficult to manufacture neoantigen peptides. GenScript collaborated with many T-cell therapy and personalized cancer vaccine companies to build the necessary infrastructure for its neoantigen peptide synthesis platform in order to successfully create challenging neoantigen peptides.
In this webinar, you will learn about the applications of neoantigen peptide, and the solution for neoantigen production, through GenScript’s proprietary technologies, for precision immunotherapy development.

свернуть